← All indications
Emergencies
Situations or conditions requiring immediate intervention to avoid serious adverse results.
Drugs by status
Phase 4 trials (15)
Phase 3 trials (4)
Other trials (3)
Organizations
Organization Involved with Phase 4 Indications (132)
- Archimedes Pharma Ltd
- EKR Therapeutics
- The Medicines Company
- Scios
- Fresenius
- Astellas
- Gilead Sciences
- AstraZeneca
- Novo Nordisk
- Sanofi
- Purdue Pharmaceuticals
- Wyeth
- Baxalta
- Bayer
- GlaxoSmithKline
- Halozyme Therapeutics
- HRA Pharma
- Mundipharma
- Otsuka
- National Institutes of Health (NIH)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- United States Army
- United States Air Force
- United States Navy
- Region Skane
- University of Pennsylvania
- Akdeniz University
- Alameda Health System
- Centre Hospitalier le Mans
- +102 more
Organization Involved with Phase 3 Indications (64)
- Forest Laboratories
- Pfizer
- Cumberland Pharmaceuticals
- Hamad Medical Corporation
- Indivior Inc.
- Lallemand SAS
- Nanjing Yoko Biomedical Co., Ltd.
- Boehringer Ingelheim
- Duramed Research
- Planned Parenthood
- National Institute of Allergy and Infectious Diseases (NIAID)
- University of Arizona
- University of Pittsburgh
- Brown University
- Centre Hospitalier de la Région d'Annecy
- Institut National de la Santé Et de la Recherche Médicale, France
- King Fahad Medical City
- King Saud University
- Melbourne Health
- Neuroscience Trials Australia
- Northwestern University
- Universidad Autonoma de Madrid
- University of Melbourne
- University of Michigan
- University of South Florida
- University of Athens
- University of Bordeaux
- Virginia Commonwealth University
- Wayne State University
- Assiut University
- +34 more
Organization Involved with Phase 2 Indications (20)
- Ocera Therapeutics
- The EMMES Corporation
- AIDS Clinical Trials Group
- Telethon Kids Institute
- Cornell University
- Monmouth Medical Center
- Newark Beth Israel Medical Center
- NHS Lothian
- Stanford University
- University of Edinburgh
- University of Monastir
- Mercy Health Partners, Cincinnati
- Louisiana State University
- St. Barnabas Medical Center, Livingston, NJ
- Insys Therapeutics Inc
- Grady Memorial Hospital, Atlanta
- University of Rennes
- Centers for Disease Control and Prevention (CDC)
- Community Medical Center, Toms River, NJ
- National Drug Abuse Treatment Clinical Trials Network
Organization Involved with Phase 1 Indications (10)
Organization Involved with Other Experimental Indications (46)
- Incyte
- Daiichi Sankyo
- Roche
- Merck
- Octapharma
- Bioelectron
- Salient Pharmaceuticals Incorporated
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
- ZonMw: The Netherlands Organisation for Health Research and Development
- National Center for Research Resources (NCRR)
- National Institute of Nursing Research (NINR)
- National Institute on Drug Abuse (NIDA)
- Maastricht University
- Baylor University
- Dartmouth University
- Eastern Virginia Medical School
- Federal University of the Valleys of Jequitinhonha and Mucuri
- Georgetown University
- Henry Ford Health System
- Queen's University, Belfast
- Rutgers University
- The Royal Bournemouth Hospital
- Tufts University
- Thomas Jefferson University
- University of Kansas
- University of Medicine and Dentistry of New Jersey
- University of Missouri, Kansas City
- University of Oklahoma
- State University of New York
- Wenzhou Medical University
- +16 more